The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom
But the drugs can leave some users feeling seriously unwell and many in hospital.
2
After scouring social media, scientists have found the most common side effects of the popular fat-busting meds.
Vomiting, nausea and headaches are the most talked-about side effects of the jabs, according to the new study, which analysed thousands of Facebook posts.
The US researchers looked at how people in the US were discussing GLP-1 drugs like Wegovy, Ozempic, and Mounjaro on public pages.
They found that gut issues were the most frequently mentioned side effects overall, especially among users of semaglutide (the active ingredient in Wegovy) and tirzepatide (the active ingredient in Mounjaro).
Mental health concerns like anxiety and depression were also raised, but far less frequently.
The study, published in JMIR Infodemiology, found that vomiting was most often mentioned in posts about Mounjaro, a drug containing tirzepatide, at 3.8 per cent.
Meanwhile, Wegovy users mentioned depression more than any other group, with 1.57 per cent of posts referencing the symptom.
The drugs, originally developed for type 2 diabetes, have soared in popularity thanks to their dramatic weight-loss effects, with celebs like Oprah Winfrey and Sharon Osbourne singing their praises.
But they've also been linked to less glamorous side effects, such as joint pain, fatigue, hair loss, and in some cases, gallbladder problems.
Despite the risks, experts say the drugs are still safe and effective for most patients.
Weight Loss Jabs - Pros vs Cons
They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes.
Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity.
In the US, this number is even higher, with over 2 per cent of the population, approximately 4 million people, currently using these medications for weight loss.
But health officials warn they are not a silver bullet and can come with side effects.
The scientists found these effects varied by brand.
Zepbound, a newer tirzepatide drug which is approved in the US but not the UK, was linked more often to high blood pressure,
While Ozempic posts mentioned gallbladder issues most. Ozempic is approved for weight loss in the US but is only approved for diabetes in the UK.
Scientists from the University of Maryland, who are behind the study, analysed nearly 60,000 unique public Facebook posts uploaded by US users of the medicines between 2022 and 2024,
They used cluster analysis to map out which symptoms were often mentioned together.
They found that vomiting, nausea and pancreatitis - a condition where the pancreas becomes inflamed - often came hand in hand, while anxiety frequently appeared alongside depression and fatigue.
Posts about side effects spiked after major events including the US Food and Drug Administration approving Wegovy for teens, celebrity endorsements, and wider insurance coverage in the US.
2
Despite these increases, the proportion of people talking about side effects actually dropped over time.
Scientists say monitoring social media could be a useful way to spot side effects that might be missed or underreported in clinical trials.
But they warned that Facebook posts don't tell the full story as symptoms were self-reported, which means they can be exaggerated or incomplete.
There is also no way to verify dosage, how long people were on the drugs, or even whether they were using genuine products.
However, the findings offer insight into what real-world users are experiencing, beyond the controlled world of clinical trials.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
10 minutes ago
- The Independent
A single injection for newborns could protect them against HIV for years, study suggests
A single injection at birth could shield children from HIV for years, a study has suggested. The study is one of the first to show that the first weeks of life offer a critical window where the immune system is naturally more tolerant, meaning it is the optimal time to deliver gene therapies that would otherwise be rejected at older ages. Researchers hope the gene therapy jab could be used in the future to fight against paediatric infections in high-risk areas. 'Nearly 300 children are infected with HIV each day,' said first author Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in the US. 'This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives.' The study, published in the journal Nature, created a gene therapy that programs cells to produce HIV-fighting antibodies. An animal study that tested the injection on non-human primates found it protected them from infection for at least three years without the need for a booster shot. But this was only if the injection was administered in the first month of life. In comparison, those that received the gene therapy between eight and 12 weeks after birth did not tolerate the treatment, study authors explain. 'This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor,' Dr Ardeshir said. 'As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself.' Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization (WHO). But if they do not receive medication, the rate of transmission of HIV from the mother to her child either during pregnancy, labour, delivery or breastfeeding ranges between 15 per cent and 45 per cent, according to WHO data. Although antiviral treatments can suppress the virus and limit transmission, adherence to treatment and doctor visits decline after childbirth, particularly in areas with limited access to healthcare, the study authors noted. This gene therapy uses a harmless virus that can deliver genetic code to cells, but is different to a vaccine. This virus was injected into muscle cells and delivered instructions to produce antibodies that are capable of neutralising multiple strains of HIV. Researchers explained that previous studies have found repeated infusions of the injection are needed for it to work. But by injecting it into muscle cells, researchers say they become 'micro-factories that just keep producing these antibodies'. Newborns showed greater tolerance to the jab, which prevented infection during breastfeeding. However, older infants and juveniles were more likely to have produced anti-drug antibodies that shut down the treatment. In addition, exposing a foetus to the antibodies from the gene therapy before birth helps older infants accept the therapy. However, because it has only been tested on animals, researchers still do not know if it will work on human children. If successful, this treatment could dramatically reduce mother-to-child HIV transmission rates in high-risk regions such as sub-Saharan Africa, where 90 per cent of paediatric HIV cases can be found. 'Nothing like this was possible to achieve even 10 years ago,' Dr Ardeshir said. 'This was a huge result, and now we have all the ingredients to take on HIV.'
Reuters
11 minutes ago
- Reuters
Humana bucks industry gloom as insurer keeps handle on medical costs
July 30 (Reuters) - Humana (HUM.N), opens new tab raised its annual profit forecast after beating quarterly estimates on Wednesday, as the U.S. health insurer succeeded in keeping its medical costs in check, in contrast to several of its rivals who recently slashed their expectations. Its shares rose 6% in early trading as the company also highlighted better-than-expected membership in its individual Medicare Advantage plans, as well as strong performance in its CenterWell care-delivery unit. Under Medicare Advantage plans, the U.S. government pays private insurers a set rate to manage healthcare for people aged 65 and older, and those with disabilities. CenterWell offers clinical programming for seniors, including primary care services and in-home health visits. Humana has been "transparent" in discussing utilization, transparency and the impact of government payment changes, said George Renaudin, president of insurance. "We reduced more benefits, and more significantly than all of our competitors in 2025." Humana reported a quarterly medical cost ratio - the percentage of premiums spent on medical care - of 89.7%, up from 88.9% a year earlier, but in line with analysts' estimates. Larger competitor UnitedHealth (UNH.N), opens new tab flagged underestimation of medical costs on Tuesday, and also provided a full-year profit forecast that fell short of analysts' already diminished estimates. The industry has been battling stubbornly high costs for the last two years due to increased use of healthcare services across government-backed plans. Humana projected full-year profit to be about $17 per share, compared with its previous estimate of about $16.25 and analyst estimates of $16.38 per share, as per LSEG data. "We think this increase will be received positively, as the company's 2025 repricing actions appear to be having their intended effect," said J.P. Morgan analyst Lisa Gill. Humana CEO Jim Rechtin said the company was confident in the growth outlook for Medicare Advantage and value-based care. Under a value-based care model, providers are paid based on how well they keep patients healthy, such as preventing hospital readmissions, which larger rival UnitedHealth has said it has struggled to integrate. UnitedHealth has been treating new value-based patients at a lower reimbursement rate than they deem as fair, said Morningstar analyst Julie Utterback. Humana said it remained optimistic that its pricing of the Medicare Advantage plans for 2025 will drive margin improvement. It also expects membership decline in the plans to be lower than previously anticipated. The company earned a second-quarter profit of $6.27 per share, topping estimates of $5.92.
The Independent
40 minutes ago
- The Independent
Lung cancer warning for foods which make up ‘half the average diet' after new study
Ultra-processed foods filled with preservatives, additives and flavour enhancers have been linked to an increased risk of lung cancer. In the UK and US, more than half of the average diet consists of ultra-processed foods (UPFs), such as ready meals, fast food and fizzy drinks. A previous BMJ study in 2024 linked UPFs to 32 harmful health effects including a higher risk of heart disease, cancer, type 2 diabetes, adverse mental health and early death. Now, eating UPFs has been linked to lung cancer - the most common cancer in the world, according to the World Cancer Research Fund. There were an estimated 2.2 million new cases and 1.8 million deaths from the disease worldwide in 2020, researchers of the study published in the respiratory journal Thorax said. But limiting consumption of these foods may help curb the global impact of the disease, the researchers say. Although there is no exact definition of a UPF, these foods typically undergo multiple processing steps, contain long lists of additives and preservatives, and are ready-to-eat or heat. Researchers drew on data from the US Prostate, Lung, Colorectal and Ovarian Cancer Screening Trials, involving 155,000 participants aged 55 to 74 who were randomly assigned to either a screening or comparison group between November 1993 and July 2001. Cancer diagnoses were tracked until the end of 2009, and cancer deaths until the end of 2018. A total of 101,732 people (50,187 men and 51,545 women, with an average age of 62) who completed a questionnaire on their dietary habits upon entry to the trials were included in the study. Foods were categorised as: unprocessed or minimally processed; containing processed culinary ingredients; processed; or ultra-processed. The researchers focused in particular on UPFs that included sour cream, as well as cream cheese, ice cream, frozen yoghurt, fried foods, bread, baked goods, salted snacks, breakfast cereals, instant noodles, shop-bought soups and sauces, margarine, confectionery, soft drinks, sweetened fruit drinks, restaurant/shop-bought hamburgers, hot dogs, and pizza. The three types of food that featured the most were lunch meat (11 per cent), diet or caffeinated soft drinks (just over 7 per cent) and decaffeinated soft drinks (nearly 7 per cent). Participants were tracked for 12 years and in that time, 1,706 new cases of lung cancer were diagnosed, including 1,473 cases of non-small cell lung cancer (NSCLC) and 233 of small cell lung cancer (SCLC). After accounting for potentially influential factors, including smoking and overall diet quality, participants who ate the most UPFs were 41 per cent more likely to be diagnosed with lung cancer than those who ate the least. Overall, they were 37 per cent more likely to be diagnosed with NSCLC and 44 per cent more likely to be diagnosed with SCLC. Because it was an observational study and no firm conclusions can be drawn about cause and effect, researchers acknowledge that they weren't able to factor in smoking intensity, which may have been influential. Dietary information was collected only once, so they could not account for changes over time, and the number of cancer diagnoses was small. But researchers do highlight the low nutritional value of UPFs and the excessive amounts of salt, sugar and fats they contain. 'The rise in UPF consumption may have driven global increases in obesity, cardiovascular disease, metabolic disorders, cancer and mortality, as these foods are confirmed risk factors for such conditions,' the researchers suggested. 'Industrial processing alters the food matrix, affecting nutrient availability and absorption, while also generating harmful contaminants,' they added, highlighting acrolein, which is found in grilled sausages and caramel sweets and is a toxic component of cigarette smoke. Packaging materials may also have a role to play, they suggested. 'You can't say from this study that UPFs cause cancer as it's observational, so we're looking at associations, not direct effects. But it does strengthen the case for looking more closely at the food environment many people are living in where UPFs are cheap, convenient, and heavily marketed, making them a go-to for many,' Rob Hobson, nutritionist and author of Unprocess Your Family Life, told The Independent. He suggested, rather than 'pointing figures at individual foods', to instead make small shifts towards a healthier diet. 'That might mean cooking more from scratch where possible, adding in more whole foods like vegetables, beans and grains, or just becoming more aware of how often UPFs show up in your day,' he said. 'It's not about being perfect, it's about balance and understanding how your food choices could be supporting or undermining your long-term health.'
